Jaguar Gene Therapy Shares New Community Letter and FAQ with Latest Jag201 Clinical Study Details on ClinicalTrials.gov

Important Links:

Dear families,

We have an important update from Jaguar Gene Therapy regarding the JAG201 clinical trial for Phelan-McDermid syndrome and genetic forms of autism spectrum disorder (ASD).

Jaguar has released an updated community letter and an FAQ document that provides new details about the clinical study. This resource addresses previously unanswered questions and offers clarity on key aspects of the study, including study site contact information.

In addition, the study is now posted on ClinicalTrials.gov, where you can find comprehensive information about the trial, including eligibility criteria and study locations.

We encourage families to review the updated letter and FAQ from Jaguar, which is designed to help you better understand all aspects of this clinical study. As always, PMSF remains committed to keeping you informed about advancements in research and treatment options.

Best,

Ronni Blumenthal

PMSF Chief Executive Officer